Table 1 Studies characteristics and quality
Study | Country | Study design | Period | Patients C/NC | Sex(male) C-NC | Age(years) C-NC | NOS grade |
|---|---|---|---|---|---|---|---|
Abe 2017 | Japan | Cohort study | 2012–2015 | 25/91 | 84 | NA | 8 |
Barenboim 2022 | Germany | Cohort study | 2000–2018 | 25/211 | 12/88 | 65 (34–83)/62 (33–82) | 9 |
Chiu 2014 | Canada | Cohort study | 2006–2012 | 24/138 | 19/100 | 66 ± 11/61.7 ± 11.11 | 7 |
Eray 2019 | Turkey | Cohort study | 2015–2018 | 12/54 | 10/40 | 61.67 ± 12.0/58.1 ± 10.9 | 7 |
Kim 2015 | Korea | Cohort study | 2004–2011 | 23/112 | 15/76 | 66 ± 11/61 ± 10 | 9 |
Kim 2016 | Korea | Cohort study | 2001–2008 | 64/609 | 49/390 | 58.5 ± 11.2/59.7 ± 10.0 | 8 |
Lee 2015 | Korea | Cohort study | 2000–2009 | 28/203 | 16/138 | more than 65 year (21/139) | 7 |
Li 2014 | China | Cohort study | 2014–2017 | 58/220 | 46/147 | 74.5 ± 5.02/73.79 ± 4.60 | 7 |
Liu 2021 | China | Cohort study | 2012–2019 | 34/232 | NA | NA | 8 |
Zhu 2022 | China | Cohort study | 2013–2019 | 52/368 | 38/250 | 62.2 ± 7.8/64.6 ± 9.6 | 8 |
Pan 2016 | China | Cohort study | 2006–2013 | 51/245 | 31/145 | 59(33–77)/59(22–87) | 8 |
Wang 2016 | China | Cohort study | 2008–2018 | 51/230 | 33/152 | more than 65 year (33/179) | 8 |
Zeman 2020 | Poland | Cohort study | 2008–2018 | 38/63 | 30/37 | 61.98 ± 10.6/61.61 ± 10.81 | 9 |
Zhang 2022 | China | Cohort study | 2011–2019 | 26/159 | 20/92 | 62(32–81)/59(25–81) | 8 |